Your browser doesn't support javascript.
loading
A topological refactoring design strategy yields highly stable granulopoietic proteins.
Skokowa, Julia; Hernandez Alvarez, Birte; Coles, Murray; Ritter, Malte; Nasri, Masoud; Haaf, Jérémy; Aghaallaei, Narges; Xu, Yun; Mir, Perihan; Krahl, Ann-Christin; Rogers, Katherine W; Maksymenko, Kateryna; Bajoghli, Baubak; Welte, Karl; Lupas, Andrei N; Müller, Patrick; ElGamacy, Mohammad.
Afiliación
  • Skokowa J; Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, 72076, Tübingen, Germany. julia.skokowa@med.uni-tuebingen.de.
  • Hernandez Alvarez B; Max Planck Institute for Biology, 72076, Tübingen, Germany.
  • Coles M; Max Planck Institute for Biology, 72076, Tübingen, Germany.
  • Ritter M; Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, 72076, Tübingen, Germany.
  • Nasri M; Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, 72076, Tübingen, Germany.
  • Haaf J; Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, 72076, Tübingen, Germany.
  • Aghaallaei N; Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, 72076, Tübingen, Germany.
  • Xu Y; Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, 72076, Tübingen, Germany.
  • Mir P; Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, 72076, Tübingen, Germany.
  • Krahl AC; Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, 72076, Tübingen, Germany.
  • Rogers KW; Friedrich Miescher Laboratory of the Max Planck Society, 72076, Tübingen, Germany.
  • Maksymenko K; Division of Developmental Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Bajoghli B; Max Planck Institute for Biology, 72076, Tübingen, Germany.
  • Welte K; Friedrich Miescher Laboratory of the Max Planck Society, 72076, Tübingen, Germany.
  • Lupas AN; Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, 72076, Tübingen, Germany.
  • Müller P; Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, 72076, Tübingen, Germany.
  • ElGamacy M; Max Planck Institute for Biology, 72076, Tübingen, Germany.
Nat Commun ; 13(1): 2948, 2022 05 26.
Article en En | MEDLINE | ID: mdl-35618709
ABSTRACT
Protein therapeutics frequently face major challenges, including complicated production, instability, poor solubility, and aggregation. De novo protein design can readily address these challenges. Here, we demonstrate the utility of a topological refactoring strategy to design novel granulopoietic proteins starting from the granulocyte-colony stimulating factor (G-CSF) structure. We change a protein fold by rearranging the sequence and optimising it towards the new fold. Testing four designs, we obtain two that possess nanomolar activity, the most active of which is highly thermostable and protease-resistant, and matches its designed structure to atomic accuracy. While the designs possess starkly different sequence and structure from the native G-CSF, they show specific activity in differentiating primary human haematopoietic stem cells into mature neutrophils. The designs also show significant and specific activity in vivo. Our topological refactoring approach is largely independent of sequence or structural context, and is therefore applicable to a wide range of protein targets.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Factor Estimulante de Colonias de Granulocitos / Hematopoyesis Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Asunto principal: Factor Estimulante de Colonias de Granulocitos / Hematopoyesis Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2022 Tipo del documento: Article País de afiliación: Alemania